NEW YORK, NY / ACCESSWIRE / October 11, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AMPE Shareholders Click Here: https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=32525&wire=1
CODX Shareholders Click Here: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32525&wire=1
HGEN Shareholders Click Here: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=32525&wire=1

* ADDITIONAL INFORMATION BELOW *

Ampio Pharmaceuticals, Inc. AMPE

This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020 and August 3, 2022, inclusive.
Lead Plaintiff Deadline: October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=32525&wire=1

According to the filed complaint, (i) defendants had inflated the Company's true ability to successfully file a Biologics License Application ("BLA") for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Co-Diagnostics, Inc. CODX

This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).
Lead Plaintiff Deadline: October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32525&wire=1

According to the filed complaint, (i) demand for the Company's Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants' positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.

Humanigen, Inc. HGEN

HGEN Lawsuit on behalf of: investors who purchased May 28, 2021 - July 12, 2022
Lead Plaintiff Deadline: October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=32525&wire=1

According to the filed complaint, during the class period, Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com: